• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Comprehensive Review of PCSK9 Inhibitors
J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221100107. doi: 10.1177/10742484221100107.ABSTRACTCardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations. However, patients who are statin intolerant or those who do not achieve their treatment goals while on high-intensity statin therapy, such as those with familial hypercholesterolemia, remain at risk. With the discovery of PCSK9 inhib...
Source: Atherosclerosis - May 20, 2022 Category: Cardiology Authors: Caroline Coppinger Mohammad Reza Movahed Veronica Azemawah Lee Peyton James Gregory Mehrnoosh Hashemzadeh Source Type: research

Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors
Am J Manag Care. 2021 Mar;27(4 Suppl):S63-S69. doi: 10.37765/ajmc.2021.88606.ABSTRACTHyperlipidemia is a prevalent condition in the United States and a significant contributor to atherosclerotic cardiovascular disease (ASCVD). ASCVD is a primary cause of morbidity and mortality in the United States. Low-density lipoprotein cholesterol (LDL-C) is a causal factor for the development of ASCVD. Reductions in LDL-C produce a corresponding decrease in ASCVD risk for cardiovascular events. HMG-CoA reductase inhibitors, commonly referred to as statins, remain the gold standard of hyperlipidemia treatment. However, statin monothera...
Source: The American Journal of Managed Care - March 12, 2021 Category: Health Management Authors: Paul B Shaw Source Type: research

Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk
Atheroscler Suppl. 2020 Dec;42:e1-e5. doi: 10.1016/j.atherosclerosissup.2021.01.001.ABSTRACTThe 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the Management of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk, that were recently released by the United States and Europe, provide new recommendations for the management of blood lipid levels based on the latest evidence. Despite many common points, there are several diff...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Lale Tokg özoğlu Manuela Casula Angela Pirillo Alberico L Catapano Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20